References

Global epidemiology of epithelial ovarian cancer.

10.1038/s41571-024-00881-3 · 2024 · External reference

Long-term results of dose-dense paclitaxel and carboplatin versus conventional paclitaxel and carboplatin for treatment of advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer (JGOG 3016): a randomised, controlled, open-label trial.

10.1016/s1470-2045(13)70363-2 · 2013 · External reference

Weekly vs. every-3-week paclitaxel and carboplatin for ovarian cancer.

10.1056/nejmoa1505067 · 2016 · External reference

Weekly dose-dense chemotherapy in first-line epithelial ovarian, fallopian tube, or primary peritoneal cancer treatment (ICON8): overall survival results from an open-label, randomised, controlled, phase 3 trial.

10.1016/s1470-2045(22)00283-2 · 2022 · External reference

Standard chemotherapy with or without bevacizumab for women with newly diagnosed ovarian cancer (ICON7): overall survival results of a phase 3 randomised trial.

10.1016/s1470-2045(15)00086-8 · 2015 · External reference

Final overall survival of a randomized trial of bevacizumab for primary treatment of ovarian cancer.

10.1200/jco.19.01009 · 2019 · External reference

ICON8B: GCIG phase III randomised trial comparing first-line weekly dose-dense chemotherapy + bevacizumab to three-weekly chemotherapy + bevacizumab in high-risk stage III-IV epithelial ovarian cancer: final overall survival (OS) analysis.

10.1016/j.ijgc.2025.102893 · 2026 · External reference

A randomized, phase III trial to evaluate rucaparib monotherapy as maintenance treatment in patients with newly diagnosed ovarian cancer (ATHENA-MONO/GOG-3020/ENGOT-ov45).

10.1200/jco.22.01003 · 2022 · External reference

Treatment with niraparib maintenance therapy in patients with newly diagnosed advanced ovarian cancer: a phase 3 randomized clinical trial.

10.1001/jamaoncol.2023.2283 · 2023 · External reference

Senaparib as first-line maintenance therapy in advanced ovarian cancer: a randomized phase 3 trial.

10.1038/s41591-024-03003-9 · 2024 · External reference

Niraparib first-line maintenance therapy in patients with newly diagnosed advanced ovarian cancer: final overall survival results from the PRIMA/ENGOT-OV26/GOG-3012 trial.

10.1016/j.annonc.2024.08.2241 · 2024 · External reference

Olaparib plus bevacizumab first-line maintenance in ovarian cancer: final overall survival results from the PAOLA-1/ENGOT-ov25 trial.

10.1016/j.annonc.2023.05.005 · 2023 · External reference

Overall survival with maintenance olaparib at a 7-year follow-up in patients with newly diagnosed advanced ovarian cancer and a BRCA mutation: the SOLO1/GOG 3004 trial.

10.1200/jco.22.01549 · 2023 · External reference

Neoadjuvant chemotherapy for newly diagnosed, advanced ovarian cancer: ASCO guideline update.

10.1200/jco-24-02589 · 2025 · External reference

ESMO Clinical Practice Guideline Express Update on the management of epithelial ovarian cancer.

10.1016/j.esmoop.2025.106032 · 2026 · External reference

TRUST: Trial of Radical Upfront Surgical Therapy in Advanced Ovarian Cancer (ENGOT ov33/AGO-OVAR OP7).

10.1200/jco.2025.43.17_suppl.lba5500 · 2025 · External reference

#1072 Assessment of the prognostic impact of the European Society of Gynecologic Oncology quality indicators for advanced ovarian cancer surgery.

10.1136/ijgc-2024-esgo.1120 · 2024 · External reference

Utilization of primary cytoreductive surgery for advanced-stage ovarian cancer.

10.1001/jamanetworkopen.2024.39893 · 2024 · External reference

Optimal bevacizumab treatment strategy in advanced ovarian cancer: a review.

10.1016/j.ctrv.2025.102945 · 2025 · External reference

Updated progression-free survival and final overall survival with maintenance olaparib plus bevacizumab according to clinical risk in patients with newly diagnosed advanced ovarian cancer in the phase III PAOLA-1/ENGOT-ov25 trial.

10.1136/ijgc-2023-004995 · 2024 · External reference

Efficacy of maintenance olaparib for patients with newly diagnosed advanced ovarian cancer with a BRCA mutation: subgroup analysis findings from the SOLO1 trial.

10.1200/jco.20.00799 · 2020 · External reference

ESGO-ESMO-ESP consensus conference recommendations on ovarian cancer: pathology and molecular biology and early, advanced and recurrent disease.

10.1016/j.annonc.2023.11.015 · 2024 · External reference

CA-125 KELIM as a potential complementary tool for predicting veliparib benefit: an exploratory analysis from the VELIA/GOG-3005 study.

10.1200/jco.22.00430 · 2023 · External reference

Chemotherapy response score: development and validation of a system to quantify histopathologic response to neoadjuvant chemotherapy in tubo-ovarian high-grade serous carcinoma.

10.1200/jco.2014.60.5212 · 2015 · External reference

The role of Chemotherapy Response Score (CRS) in the decision making process for patients with advanced high grade serous ovarian cancer undergoing neoadjuvant chemotherapy.

10.1200/jco.2023.41.16_suppl.5591 · 2023 · External reference

Integrating clinical-molecular data to predict PARP inhibitors efficacy in advanced ovarian cancer patients after interval cytoreductive surgery.

10.1016/j.ygyno.2025.02.016 · 2025 · External reference

Benefit from fractionated dose-dense chemotherapy in patients with poor prognostic ovarian cancer: ICON-8 trial.

10.1200/cci.22.00188 · 2023 · External reference

Survival and modelled cancer antigen-125 ELIMination rate constant K score in ovarian cancer patients in first-line before poly(ADP-ribose) polymerase inhibitor era: a Gynaecologic Cancer Intergroup meta-analysis.

10.1016/j.ejca.2023.112966 · 2023 · External reference

Confirmation of the utility of the CA-125 elimination rate (KELIM) as an indicator of the chemosensitivity in advanced-stage ovarian cancer in a “real-life setting”.

10.3802/jgo.2024.35.e34 · 2024 · External reference

CA-125 ELIMination Rate Constant K (KELIM) is a marker of chemosensitivity in patients with ovarian cancer: results from the phase II CHIVA trial.

10.1158/1078-0432.ccr-20-0054 · 2020 · External reference

The role of the tumor primary chemosensitivity relative to the success of the medical-surgical management in patients with advanced ovarian carcinomas.

10.1016/j.ctrv.2021.102294 · 2021 · External reference

Clinical impact of CA-125 ELIMination rate constant K (KELIM) on surgical strategy in advanced serous ovarian cancer patients.

10.1136/ijgc-2023-004872 · 2024 · External reference

Quality indicators for advanced ovarian cancer surgery from the European Society of Gynaecological Oncology (ESGO): 2020 update.

10.1136/ijgc-2020-001248 · 2020 · External reference

Predictive impact of clinical factors on chemosensitivity in advanced high-grade serous ovarian carcinoma according to chemotherapy response score.

10.1097/md.0000000000040487 · 2024 · External reference

Germline BRCA1/2 status and chemotherapy response score in high-grade serous ovarian cancer.

10.1038/s41416-024-02874-6 · 2024 · External reference

Predictors of successful neoadjuvant chemotherapy and interval cytoreductive surgery in management of ovarian cancer.

10.1200/op-25-00469 · 2025 · External reference

Objective responses to first-line neoadjuvant carboplatin-paclitaxel regimens for ovarian, fallopian tube, or primary peritoneal carcinoma (ICON8): post-hoc exploratory analysis of a randomised, phase 3 trial.

10.1016/s1470-2045(20)30591-x · 2021 · External reference

The role of CT, PET-CT, and MRI in ovarian cancer.

10.1259/bjr.20210117 · 2021 · External reference

A comparative study of [68Ga]Ga-FAPI-04 PET/MR and [18F]FDG PET/CT in the diagnostic accuracy and resectability prediction of ovarian cancer.

10.1007/s00259-023-06235-y · 2023 · External reference

Integrated radiogenomics models predict response to neoadjuvant chemotherapy in high grade serous ovarian cancer.

10.1038/s41467-023-41820-7 · 2023 · External reference

Circulating tumor DNA as a biomarker for predicting progression-free survival and overall survival in patients with epithelial ovarian cancer: a systematic review and meta-analysis.

10.1136/ijgc-2024-005313 · 2024 · External reference

Tracking clonal evolution during treatment in ovarian cancer using cell-free DNA.

10.1038/s41586-025-09580-0 · 2025 · External reference

Prognostic value of circulating tumor DNA at diagnosis and its early decrease after one cycle of neoadjuvant chemotherapy for patients with advanced epithelial ovarian cancer: an ancillary analysis of the CHIVA phase II GINECO trial.

10.1016/j.ygyno.2024.12.004 · 2025 · External reference

Comparative analysis of predictive values of the kinetics of 11 circulating miRNAs and of CA125 in ovarian cancer during first line treatment (a GINECO study).

10.1016/j.ygyno.2020.07.021 · 2020 · External reference

Ex vivo 3D micro-tumour testing platform for predicting clinical response to platinum-based therapy in patients with high-grade serous ovarian cancer.

10.1038/s41698-025-01080-8 · 2025 · External reference

Impact of KELIM chemosensitivity and interval cytoreduction on survival outcomes from neoadjuvant weekly dose-dense paclitaxel +/- bevacizumab: pooled analysis of ICON8 and ICON8B phase III trials.

10.1016/j.ijgc.2025.102892 · 2026 · External reference

109RO Continuous relationship between KELIM chemosensitivity and survival benefit from chemotherapy intensification (standard or dose-dense; with/without bevacizumab): ICON8 & 8B.

10.1016/j.esmoop.2026.108156 · 2026 · External reference

A phase 3 trial of bevacizumab in ovarian cancer.

10.1056/nejmoa1103799 · 2011 · External reference

Bevacizumab for newly diagnosed ovarian cancers: best candidates among high-risk disease patients (ICON-7).

10.1093/jncics/pkaa026 · 2020 · External reference

Identification of patients with ovarian cancer experiencing the highest benefit from bevacizumab in the first-line setting on the basis of their tumor-intrinsic chemosensitivity (KELIM): the GOG-0218 validation study.

10.1200/jco.22.01207 · 2022 · External reference

Veliparib concomitant with first-line chemotherapy and as maintenance therapy in ovarian cancer: final overall survival and disease-related symptoms results.

10.1016/j.ejca.2025.115587 · 2025 · External reference

Atezolizumab, bevacizumab, and chemotherapy for newly diagnosed stage III or IV ovarian cancer: placebo-controlled randomized phase III trial (IMagyn050/GOG 3015/ENGOT-OV39).

10.1200/jco.21.00306 · 2021 · External reference

Impact of adding the immune checkpoint inhibitor atezolizumab to first-line chemotherapy on progression-free survival in poor-prognosis ovarian cancer: a retrospective analysis from the IMagyn050 trial.

10.1016/j.ygyno.2025.04.577 · 2025 · External reference

Neoadjuvant and adjuvant pembrolizumab in advanced high-grade serous carcinoma: the randomized phase II NeoPembrOV clinical trial.

10.1038/s41467-024-46999-x · 2024 · External reference

Immunomic longitudinal profiling of the NeoPembrOv trial identifies drivers of immunoresistance in high-grade ovarian carcinoma.

10.1038/s41467-024-47000-5 · 2024 · External reference

Bevacizumab combined with chemotherapy for platinum-resistant recurrent ovarian cancer: the AURELIA open-label randomized phase III trial.

10.1200/jco.2013.51.4489 · 2014 · External reference

Efficacy and safety of bevacizumab-containing neoadjuvant therapy followed by interval debulking surgery in advanced ovarian cancer: results from the ANTHALYA trial.

10.1016/j.ejca.2016.09.036 · 2017 · External reference

Analysis of tumor microenvironment changes after neoadjuvant chemotherapy with or without bevacizumab in advanced ovarian cancer (GEICO-89T/MINOVA study).

10.1158/1078-0432.ccr-23-0771 · 2024 · External reference

Neoadjuvant pamiparib in patients with newly diagnosed advanced ovarian cancer: a single-arm, prospective phase II trial.

10.1200/jco.2024.42.16_suppl.e17555 · 2024 · External reference

The NUVOLA TRIAL: neoadjuvant chemoteraphy in unresectable ovarian cancer with olaparib and weekly carboplatin plus paclitaxel: a phase II open-label multi-centre study.

10.1136/ijgc-2023-esgo.903 · 2023 · External reference

Chemotherapy with or without avelumab followed by avelumab maintenance versus chemotherapy alone in patients with previously untreated epithelial ovarian cancer (JAVELIN Ovarian 100): an open-label, randomised, phase 3 trial.

10.1016/s1470-2045(21)00342-9 · 2021 · External reference

FIRST/ENGOT-OV44: a phase 3 clinical trial of dostarlimab (dost) and niraparib (nira) in first-line (1L) advanced ovarian cancer (aOC).

10.1200/jco.2025.43.17_suppl.lba5506 · 2025 · External reference

LBA30 ATHENA-COMBO, a phase III, randomized trial comparing rucaparib (RUCA) + nivolumab (NIVO) combination therapy vs RUCA monotherapy as maintenance treatment in patients (pts) with newly diagnosed ovarian cancer (OC).

10.1016/j.annonc.2024.08.2269 · 2024 · External reference

Durvalumab with carboplatin/paclitaxel and bevacizumab followed by durvalumab and bevacizumab with or without olaparib maintenance in newly diagnosed non-BRCA-mutated advanced ovarian cancer.

10.1016/j.annonc.2025.11.020 · 2026 · External reference

Immunotherapy advancements in high-grade serous ovarian cancer: from promise to practice.

10.1016/j.critrevonc.2026.105312 · 2026 · External reference

Phase Ib INEOV neoadjuvant trial of durvalumab +/- tremelimumab with platinum chemotherapy for patients (pts) with unresectable ovarian cancer (OC): survival outcomes and immune correlates.

10.1200/jco.2024.42.16_suppl.5569 · 2024 · External reference

Exploring the therapeutic use and outcome of antibody-drug conjugates in ovarian cancer treatment.

10.1038/s41388-025-03448-3 · 2025 · External reference

Enhancing therapeutic response and overcoming resistance to checkpoint inhibitors in ovarian cancer through cell cycle regulation.

10.3390/ijms251810018 · 2024 · External reference

A Mucin 16 bispecific T cell-engaging antibody for the treatment of ovarian cancer.

10.1126/scitranslmed.aau7534 · 2019 · External reference

CAR-T cell immunotherapy for ovarian cancer: hushing the silent killer.

10.3389/fimmu.2023.1302307 · 2023 · External reference

Hyperthermic intraperitoneal chemotherapy for recurrent ovarian cancer (CHIPOR): a randomised, open-label, phase 3 trial.

10.1016/s1470-2045(24)00531-x · 2024 · External reference

Effect of HIPEC according to HRD/BRCAwt genomic profile in stage III ovarian cancer: results from the phase III OVHIPEC trial.

10.1002/ijc.34124 · 2022 · External reference

Utility of CA125 KELIM in predicting benefit from hyperthermic intraperitoneal chemotherapy in patients with advanced ovarian cancer: pooled analysis of KGOG3042 and KOV-HIPEC-01.

10.1016/j.ijgc.2025.102746 · 2026 · External reference

SALVOVAR: a pragmatic randomized phase III trial comparing the SALVage weekly dose-dense regimen to the standard 3-weekly regimen in patients with poor prognostic OVARian cancers.

10.1177/17588359251396777 · 2025 · External reference

Personalised chemotherapy based on tumour marker decline in poor prognosis germ-cell tumours (GETUG 13): a phase 3, multicentre, randomised trial.

10.1016/s1470-2045(14)70490-5 · 2014 · External reference

Trastuzumab emtansine for residual invasive HER2-positive breast cancer.

10.1056/nejmoa1814017 · 2019 · External reference

Unresolved reference

2025 · External reference

Unresolved reference

2026 · External reference

Unresolved reference

External reference

Unresolved reference

External reference